Cell and gene therapy development differs sharply from traditional drug development. Treatments consist of live cells, DNA or RNA sequences, or genetically modified immune cells; development is complicated and often personalized; and manufacturing requires special GMP facilities, cell processing, and viral vector production that are complicated to scale. These features explain why sponsors turn to CROs. Polaris Market Research values the market at USD 5.28 billion in 2025, with a projected CAGR of 9.84% from 2026 to 2034.
Funding and Technology Momentum
Government and private funding in areas such as gene editing, immunotherapies, and personalized medicine is expanding globally. In March 2025, Arbor Biotechnologies closed a USD 73.9 million Series C financing round to advance next-generation therapeutics, supporting its lead candidate ABO-101 for primary hyperoxaluria type 1. The report adds that rapid innovation in CRISPR-Cas9, viral vector engineering, and CAR-T therapies is accelerating demand for CROs with domain-specific expertise, access to GMP environments, and understanding of evolving regulations.
Non-Viral Delivery Gains Ground
Among delivery platforms, the lipid nanoparticle segment is anticipated to register the highest growth rate, at 11.2% CAGR. Rising use of mRNA-based treatments and novel nucleic acid delivery systems is increasing applications of the technology in cell and gene therapy development. Investment in non-viral systems, together with their scalability, reduced immunogenicity, and potential for multiple dosing, creates opportunities for CROs working on drug formulation and development.
Long-Term Monitoring and Logistics
The long-term follow-up development stage is projected to grow at a 9.9% CAGR, as regulators require increasing monitoring of patients to determine long-term safety, effectiveness, and any late adverse effects. Rising adoption of genome editing and gene-engineered therapies adds to this need. CROs offering pharmacovigilance and real-world evidence services are expected to benefit. Trials also involve logistical complexity, including coordinated schedules, specialized facilities, and temperature control of patient samples and treatments, along with site readiness and traceability requirements.
Support for CAR-T Development
CROs have been instrumental in CAR-T development through their knowledge of cell engineering and modification of immune cells. They help develop manufacturing processes, run testing and documentation, monitor safety, and manage clinical trials, which enables pharmaceutical companies to pursue personalized cancer treatments more efficiently. Increased funding for CAR-T development is expected to raise demand for CROs with advanced oncology expertise.
Infrastructure and Talent Constraints
CROs can provide GMP manufacturing, viral vector manufacturing, cell processing, quality control, process development, and manufacturing scale-up. However, setting up and maintaining GMP-compliant facilities requires high capital and operating expenditure, and there is an insufficient number of experienced specialists in fields such as viral vector development, cell manufacturing, and regulatory affairs. These factors may limit how quickly CROs scale up, and smaller players find it harder to compete with providers offering wider capabilities.
Browse In-depth Market Research Report:
AI and Deal Activity
AI is being applied to analyze genetic, biomarker, and clinical data to identify eligible patients, while machine learning helps select trial sites and forecast recruitment. Consolidation continues: in January 2026, Avance Clinical announced the acquisition of LumaBridge, a U.S.-based CRO with oncology expertise, and WEP Clinical announced the acquisition of Netherlands-based Siron Clinical to expand its Phase I–IV trial capabilities. Key companies in the market include:
- Altasciences
- Allucent
- Aixial Group
- CMIC Group
- ICON plc
- Fortrea
- Linical
- Medpace, Inc.
- Novotech
- PharmaLex (Part of Cencora)
- PPD (Thermo Fisher Scientific, Inc.)
- Precision for Medicine
- QPS Holdings, LLC
- Syneos Health, Inc.
- Syngene International Limited
- Parexel
- Avance Clinical
Conclusion
The cell & gene therapy contract research organizations market is shaped by technical complexity as much as by demand. Non-viral delivery, long-term patient monitoring, and AI-enabled trial planning are widening the scope of CRO services, while talent shortages and facility costs limit capacity. Providers that invest in specialized infrastructure and regulatory expertise are likely to strengthen their positions.
More Trending Latest Reports By Polaris Market Research:
Bone Grafts And Substitutes Market
Fintech as a Service (FaaS) Market
Concrete Repair Mortars Market